Intellia Therapeutics (NTLA) PT Lowered to $110 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts NTLA Hot Sheet
Price: $11.86 --0%
Rating Summary:
22 Buy, 9 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Rating Summary:
22 Buy, 9 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Join SI Premium – FREE
JMP Securities analyst Silvan Tuerkcan lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $110.00 (from $165.00) while maintaining a Market Outperform rating.
You May Also Be Interested In
- Intellia completes enrollment in Phase 3 nex-z trial for nerve disease
- Blue Owl Capital (OWL) PT Lowered to $15 at Raymond James
- Columbus McKinnon (CMCO) PT Raised to $30 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
